Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong Finance14:21

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38

Express News | The tenth batch of national centralized procurement will open bids in Shanghai tomorrow: involving 62 varieties, with strict measures to prevent companies from colluding and manipulating the bidding.

BreakingsDec 11 17:13

John Lee Ka-chiu: The long-term goal is to establish the Hong Kong Drug Administration to jointly leverage the advantages of clinical trials with the Mainland.

During an interview with RTHK, Chief Executive John Lee Ka-chiu stated that the long-term goal of the authorities is to have its own drug regulatory agency that can approve medicines and medical devices. To achieve this goal, it is necessary to establish an office to prepare, including the need to join international organizations and strengthen clinical research. John Lee mentioned that Hong Kong and the mainland can jointly leverage advantages in clinical trials, including utilizing mainland data, such as patient databases from the 1.4 billion population or nearly 80 million people in the Greater Bay Area. When top-tier clinical trials can be conducted, pharmaceutical companies can be attracted to Hong Kong, increasing the city's competitiveness and business opportunities.

AASTOCKSDec 11 09:34

December 10 A-share investment risk avoidance | Shenzhen SDG Service: Shareholder Silver Kun Company and Longxin Construction plan to collectively shareholding not exceeding 2%.

Pharmaron's major shareholder, Xinchong Kangcheng, and his concerted actors completed a shareholding reduction of 16 million shares; two shareholders of Zhixin Precision intend to collectively reduce their shares by no more than 3.0375%; shareholders of Shenzhen SDG Service, Yinkun Company and Longxin Construction intend to collectively reduce their shares by no more than 2%; Wuxi Zhenhua's shareholder Wuxi Jinfengyu intends to reduce his shares by 3%; Hainan Poly Pharm is under investigation by the Securities Regulatory Commission due to risks of being subject to significant illegal delisting of stocks; Zhejiang Yiming Food's stocks have been涨停 for 10 consecutive trading days, posing a risk of a sharp decline in the short term; Tibet Summit Resources received a warning letter from the Tibet Securities Regulatory Bureau.

Gelonghui FinanceDec 9 22:20

Pharmaron (300759.SZ) major shareholder Xinzhi Kangkang's concerted action has completed a shareholding reduction of 16 million shares.

Pharmaron (300759.SZ) announced that the shareholder holding more than 5% of the shares, Shenzhen Xinzhongkangcheng Investment Partnership...

Zhitong FinanceDec 9 19:51